PATTERSON LEONE D 4

What Happened Patterson Leone, a director of Kalaris Therapeutics (KLRS), was granted a derivative award representing 9,000 shares on June 3, 2026. The Form 4 reports the acquisition price as $0.00, indicating a compensation award (e.g., options or RSUs) rather than an open-market purchase. This was a grant/award — not a sale or exercise — and does not by itself indicate buying pressure.

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 4, 2026 (timely filing).
• Reported amount: 9,000 shares; reported price $0.00 (derivative award).
• Shares owned after transaction: not specified in the information provided in this summary.
• Footnote: The award vests in full on the earlier of (i) June 3, 2027 or (ii) the issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
• Transaction code: "A" — grant/award/other acquisition (derivative).

Context This is a typical equity compensation grant to an insider and differs from a market purchase or sale. Because it’s a grant (not an exercise or sale), it signals company compensation practice rather than an immediate change in insider holdings or market action. Vesting is time- or event-based and requires continued service; any future exercises or sales would generate separate filings.